Trials / Conditions / Relapsed Neuroblastoma

Relapsed Neuroblastoma

19 registered clinical trials studyying Relapsed Neuroblastoma — 10 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma NCT07211737	Baylor College of Medicine	Phase 1
Recruiting	Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma NCT07502287	Beijing Biotech	Phase 1 / Phase 2
Recruiting	Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Rel NCT07027748	Steven DuBois, MD	Phase 1
Recruiting	PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma NCT07007117	Stephan Grupp MD PhD	Phase 1
Recruiting	PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors NCT06721689	Theodore Laetsch	Phase 1 / Phase 2
Recruiting	Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma NCT06803875	Roberto Chiarle	Phase 1 / Phase 2
Recruiting	A Multi-Arm, Platform Trial For Relapsed Neuroblastoma NCT07334301	University of Birmingham	Phase 1 / Phase 2
Recruiting	Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or R NCT05400603	Emory University	Phase 1
Recruiting	GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma NCT05650749	Stephan Grupp MD PhD	Phase 1
Recruiting	NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab NCT04211675	Nationwide Children's Hospital	Phase 1 / Phase 2
Terminated	67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapse NCT04023331	Clarity Pharmaceuticals Ltd	Phase 1 / Phase 2
Active Not Recruiting	C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL NCT03635632	Baylor College of Medicine	Phase 1
Unknown	DNA Vaccination Against Neuroblastoma NCT04049864	Belarusian Research Center for Pediatric Oncology, Hematology and Immunology	EARLY_Phase 1
Withdrawn	Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and H NCT03209869	University of Wisconsin, Madison	Phase 1
Withdrawn	Standardized Protocol of Surgery and Radiation for Patients With Brain Metastases in Relapsed Neuroblastoma NCT03406273	Giselle Sholler	N/A
Completed	MIBG for Refractory Neuroblastoma and Pheochromocytoma NCT01850888	Masonic Cancer Center, University of Minnesota	N/A
Active Not Recruiting	Parental Decision-Making for Children With Relapsed Neuroblastoma NCT02282735	Dana-Farber Cancer Institute	—
Completed	A Trial Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma NCT01109238	Giselle Sholler	—
No Longer Available	131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma NCT03649438	University of Texas Southwestern Medical Center	—